Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2022-01-03 Capital/Financing Update
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a specific event: a €2 million grant received by the PhagECOLI project involving Pherecydes Pharma and the CEA from Bpifrance. This is a time-sensitive announcement regarding financing/funding for a specific project, not a comprehensive annual report (10-K), an interim report (IR), or a formal regulatory filing like a proxy statement or insider trade report. It fits best under Capital/Financing Update (CAP) as it details the receipt of significant grant funding that impacts the company's financial resources and project development. It is not a general regulatory filing (RNS) because it is highly specific to financing/grants.
2022-01-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 91% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Pherecydes Pharma and CEA received a €2M grant from Bpifrance for the PhagECOLI project. This is a general announcement regarding funding/project development, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is a press release announcing a specific, non-financial operational/funding event, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially Capital/Financing Update (CAP) if the focus was purely on the capital received. However, the primary nature is a public announcement of a project milestone/grant, making RNS the most appropriate general fit, although CAP is a close secondary candidate. Given the context of funding news, I will classify it as a general Regulatory Filing (RNS) as it is a broad press release about a partnership and grant, which often falls into this category when specific codes like 'CAP' are reserved for more formal financing activities (like issuing shares or debt). The length (7718 chars) is substantial enough that it is not just a brief notification of a report being available (RPA).
2022-01-03 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated December 22, 2021, announcing that Pherecydes Pharma has received authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) to start a Phase I/II clinical study (PhagoDAIR) for treating prosthetic joint infections caused by *Staphylococcus aureus* using precision phage therapy. This is an announcement about regulatory approval for a clinical trial and future business development, not a formal periodic financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). It is a general corporate update regarding clinical progress and regulatory milestones. Since it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which often captures significant operational or regulatory news releases that aren't strictly financial reporting.
2021-12-22 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated December 22, 2021, announcing that Pherecydes Pharma has obtained approval from the ANSM (French National Agency for the Safety of Medicines) to start a Phase I/II clinical study (PhagoDAIR). It details the study's purpose (precision phage therapy for osteoarticular infections), timeline (enrollment in Spring 2022, results in Summer 2023), and includes management commentary and boilerplate 'About Us' and 'Disclaimer' sections typical of corporate news releases. This content is an announcement of a significant operational/clinical development milestone, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). It is a general corporate announcement. Since it does not fit the specific categories like Capital/Financing (CAP), Director's Dealing (DIRS), or Dividend Notice (DIV), the most appropriate general category for a significant, non-standard corporate update that is not a formal report is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous regulatory/corporate news that doesn't fit elsewhere, or potentially 'Report Publication Announcement' (RPA) if it were announcing the publication of a formal report, which it is not. Given the nature of the announcement (regulatory approval for a clinical trial), RNS is the best fit as a general regulatory/corporate news item.
2021-12-22 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 98% confidence The document is a press release dated December 16, 2021, announcing that Pherecydes Pharma has been granted a patent in China for its anti-*Staphylococcus aureus* phages. The content focuses on intellectual property (IP) protection, patent grants in various jurisdictions (China, Israel, US, Europe, Japan, etc.), and the company's development pipeline. This type of announcement, which details the status of intellectual property rights, fits best under the 'Intellectual Property' category, which corresponds to the 'IP' filing code. It is not a financial report (10-K, IR, ER), a management change (MANG), or a dividend notice (DIV). It is a specific corporate update related to assets/rights.
2021-12-16 French
Inside Information / Other news releases
Investor Presentation Classification · 95% confidence The document is a press release dated December 16, 2021, announcing that Pherecydes Pharma has been granted a patent in China for its anti-Staphylococcus aureus phages. The content focuses on intellectual property protection, patent grants, and company pipeline updates, rather than routine financial reporting (like 10-K, ER, IR) or specific corporate actions (like AGM, DIV, DIRS). Since the document is an announcement about a specific, non-financial corporate development (IP protection), and it does not fit into the primary financial filing categories, it is best classified as a general Regulatory Filing (RNS) or potentially Investor Presentation (IP) if it were more strategic. Given the nature of a patent grant announcement, which is often disclosed via regulatory channels, RNS is the most appropriate general category for non-standard, material announcements. It is not a Call Transcript (CT), Earnings Release (ER), or a formal report like 10-K or IR. It is a material announcement, but not one of the highly specific types listed.
2021-12-16 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.